Hamps Bio Ltd.
BBSE:HAMPS25.00
INR
0.00
(0.00%)
ISIN
INE0QBD01018
Return %
Stock
S&P 500
1Y
14.47
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Semi-annual Revenue
INR
•
in mil. unless spec.Semi-annual Earnings Per Share
INR
•
in mil. unless spec.Semi-annual Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Herrik Mountbaton Shah
- Full Time Employees
- 51
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Surat India
- IPO Date
- Dec 20, 2024
- Website
- hampsbio.com
- Similar Companies
- Business
- Hamps Bio Ltd. is an India-based pharmaceutical, nutraceutical, and healthcare manufacturing company that develops, formulates, manufactures, and commercializes finished dosage formulations, dietary supplements, and personal care products. Headquartered in Ahmedabad, Gujarat, India, and incorporated in 2007, the company operates across pharmaceutical, ayurvedic, and wellness segments, catering to domestic retail healthcare networks, hospitals, institutional buyers, and international export markets. The company offers a diversified portfolio of healthcare and therapeutic solutions across multiple delivery formats and medical categories. Its primary product and service offerings comprise solid and liquid oral dosage formulations, including generic and branded tablets, hard and soft gelatin capsules, dry syrups, and oral suspensions for anti-infective, analgesic, anti-inflammatory, gastrointestinal, cardiovascular, and respiratory indications; sterile and topical preparations, including ophthalmic drops, dermatological creams, therapeutic gels, ointments, lotions, and medicated soaps; nutraceutical and dietary wellness products, such as multivitamin complexes, mineral supplements, antioxidant formulations, protein powders, effervescent tablets, and immunity boosters; ayurvedic and herbal remedies, including standardized botanical extracts, digestive tonics, joint-care oils, and vitality supplements; and specialized contract development and manufacturing organization (CDMO) services, encompassing formulation development, private-label manufacturing, analytical testing, regulatory dossier preparation, and custom packaging for third-party pharmaceutical and wellness enterprises. Geographically, Hamps Bio Ltd. distributes its formulations across key states and union territories in India through an extensive network of distributors, pharmacies, hospitals, and healthcare institutions. The company also exports its therapeutic and dietary products to emerging international markets across Africa, Southeast Asia, the Middle East, and Latin America, complying with regional drug regulatory frameworks and international export standards. In recent developments, Hamps Bio Ltd. has undertaken strategic initiatives to expand its manufacturing infrastructure and diversify its revenue streams. The company has enhanced its production capabilities by upgrading its formulation facilities to comply with revised Good Manufacturing Practice standards, thereby increasing batch capacity for high-demand oral solids and liquid lines. To capitalize on growing consumer demand for preventive healthcare, Hamps Bio Ltd. expanded its nutraceutical and wellness portfolio through the introduction of specialized lifestyle management supplements, organic botanical blends, and targeted immunity formulations. Operationally, the company has strengthened its CDMO business vertical, entering into manufacturing and supply arrangements with domestic healthcare brands and global trading partners. Furthermore, Hamps Bio Ltd. has pursued commercial registration expansions in overseas jurisdictions to accelerate its international export footprint, while optimizing its supply chain and corporate governance frameworks to support sustained operational growth.